Jiangsu Hengrui Pharmaceutical Co., Ltd.

Hengrui Medicine is a leading pharmaceutical company based in China with a focus on research, development, manufacturing, and commercialization of innovative and high-quality healthcare products. The company ranks top 30 worldwide by a market capitalization of over 30 billion USD, and is home to more than 21,000 employees worldwide. Hengrui owns 10 R&D centers globally, running more than 120 clinical trials worldwide. With 4 innovative drugs (imrecoxib, apatinib, mecapegfilgrastim, and pyrotinib) launched in China, 1 product under NDA review, 30+ drug candidates in clinical development worldwide, and 50+ in pre-clinical stage, Hengrui is strengthening its leadership in oncology while diversifying its portfolio covering diabetes, pain management, autoimmune, CV/metabolics, and infectious diseases. Hengrui fully owns 8 manufacturing facilities for small and large molecules as well as medical devices. All facilities are approved and audited by NMPA, most also approved by US FDA, EDQM, TGA, and PMDA. Embracing the spirit of “Honesty and Trustworthiness, Quality First” as a business principle, Hengrui leads the Chinese markets for anti-cancer drugs, surgical anesthetics, specialized infusions, and contrast agents. To date, Hengrui has 10+ products approved in Europe, US, and Japan, covering injectables, oral formulations, and inhalational anesthetics, and has achieved remarkable sales in those markets.